Drug Information

General Information
Drug ID
DR00483
Drug Name
Azelastine
Synonyms
4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride; 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone HCl; 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one; Astelin (TN); Astepro (TN); Azelastina; Azelastina [INN-Spanish]; Azelastine (INN); Azelastine [INN:BAN]; Azelastinum; Azelastinum [INN-Latin]; Optivar; Optivar (TN)
Drug Type
Small molecular drug
Therapeutic Class
Antiallergic Agents
Structure
3D MOL 2D MOL
Formula
C22H24ClN3O
Canonical SMILES
CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
InChI
InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3
InChIKey
MBUVEWMHONZEQD-UHFFFAOYSA-N
CAS Number
CAS 58581-89-8
Pharmaceutical Properties Molecular Weight 381.9 Topological Polar Surface Area 35.9
Heavy Atom Count 27 Rotatable Bond Count 3
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 3
XLogP
4.4
PubChem CID
2267
PubChem SID
103188977 , 104300096 , 11373087 , 11484393 , 11488465 , 11491799 , 124893571 , 125353726 , 126686074 , 128573214 , 131344384 , 134337644 , 135027355 , 137175390 , 139157643 , 14829436 , 152034299 , 160964310 , 162173200 , 162876873 , 163414086 , 164788079 , 164833138 , 172912872 , 174007265 , 176485063 , 178103698 , 179116569 , 179499903 , 184643901 , 210279616 , 210281939 , 29221440 , 4503340 , 46507582 , 47953967 , 48415598 , 50010207 , 50122563 , 50854757 , 51091808 , 57321230 , 7978748 , 81040982 , 8151525 , 85209838 , 85788529 , 87245030 , 87350406 , 9970
TTD Drug ID
D00JVR

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.